184 related articles for article (PubMed ID: 34129859)
21. Exploiting immune-dependent effects of microtubule-targeting agents to improve efficacy and tolerability of cancer treatment.
Serpico AF; Visconti R; Grieco D
Cell Death Dis; 2020 May; 11(5):361. PubMed ID: 32398657
[TBL] [Abstract][Full Text] [Related]
22. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
23. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells.
Marcus AI; Peters U; Thomas SL; Garrett S; Zelnak A; Kapoor TM; Giannakakou P
J Biol Chem; 2005 Mar; 280(12):11569-77. PubMed ID: 15653676
[TBL] [Abstract][Full Text] [Related]
24. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
25. Targeting mitotic exit for cancer treatment.
Wäsch R
Expert Opin Ther Targets; 2011 Jul; 15(7):785-8. PubMed ID: 21476883
[TBL] [Abstract][Full Text] [Related]
26. Mitosis-targeting therapies: a troubleshooting guide.
Doménech E; Malumbres M
Curr Opin Pharmacol; 2013 Aug; 13(4):519-28. PubMed ID: 23583638
[TBL] [Abstract][Full Text] [Related]
27. Cell type variation in responses to antimitotic drugs that target microtubules and kinesin-5.
Shi J; Orth JD; Mitchison T
Cancer Res; 2008 May; 68(9):3269-76. PubMed ID: 18451153
[TBL] [Abstract][Full Text] [Related]
28. Mitotic drug targets.
Kaestner P; Bastians H
J Cell Biochem; 2010 Oct; 111(2):258-65. PubMed ID: 20518069
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the cellular and antitumor effects of MPI-0479605, a small-molecule inhibitor of the mitotic kinase Mps1.
Tardif KD; Rogers A; Cassiano J; Roth BL; Cimbora DM; McKinnon R; Peterson A; Douce TB; Robinson R; Dorweiler I; Davis T; Hess MA; Ostanin K; Papac DI; Baichwal V; McAlexander I; Willardsen JA; Saunders M; Christophe H; Kumar DV; Wettstein DA; Carlson RO; Williams BL
Mol Cancer Ther; 2011 Dec; 10(12):2267-75. PubMed ID: 21980130
[TBL] [Abstract][Full Text] [Related]
30. Combinatorial Use of Chitosan Nanoparticles, Reversine, and Ionising Radiation on Breast Cancer Cells Associated with Mitosis Deregulation.
Piña Olmos S; Díaz Torres R; Elbakrawy E; Hughes L; Mckenna J; Hill MA; Kadhim M; Ramírez Noguera P; Bolanos-Garcia VM
Biomolecules; 2019 May; 9(5):. PubMed ID: 31083605
[TBL] [Abstract][Full Text] [Related]
31. Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.
Schmidt M; Bastians H
Drug Resist Updat; 2007; 10(4-5):162-81. PubMed ID: 17669681
[TBL] [Abstract][Full Text] [Related]
32. Growth suppression and mitotic defect induced by JNJ-7706621, an inhibitor of cyclin-dependent kinases and aurora kinases.
Matsuhashi A; Ohno T; Kimura M; Hara A; Saio M; Nagano A; Kawai G; Saitou M; Takigami I; Yamada K; Okano Y; Shimizu K
Curr Cancer Drug Targets; 2012 Jul; 12(6):625-39. PubMed ID: 22463590
[TBL] [Abstract][Full Text] [Related]
33. Shared and separate functions of polo-like kinases and aurora kinases in cancer.
Lens SM; Voest EE; Medema RH
Nat Rev Cancer; 2010 Dec; 10(12):825-41. PubMed ID: 21102634
[TBL] [Abstract][Full Text] [Related]
34. Advances in mitotic inhibitors for cancer treatment.
Jiang N; Wang X; Yang Y; Dai W
Mini Rev Med Chem; 2006 Aug; 6(8):885-95. PubMed ID: 16918495
[TBL] [Abstract][Full Text] [Related]
35. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
36. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
37. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
38. Mitosis as an anti-cancer target.
Janssen A; Medema RH
Oncogene; 2011 Jun; 30(25):2799-809. PubMed ID: 21339734
[TBL] [Abstract][Full Text] [Related]
39. Targeting mitosis for anti-cancer therapy.
Sudakin V; Yen TJ
BioDrugs; 2007; 21(4):225-33. PubMed ID: 17628120
[TBL] [Abstract][Full Text] [Related]
40. In vivo tumor imaging using polo-box domain of polo-like kinase 1 targeted peptide.
Kim SM; Yoon S; Choi N; Hong KS; Murugan RN; Cho G; Ryu EK
Biomaterials; 2012 Oct; 33(29):6915-25. PubMed ID: 22795848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
